Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSmith & Nephew Regulatory News (SN.)

Share Price Information for Smith & Nephew (SN.)

Share Price is delayed by 15 minutes
Get Live Data
1,140.00    9.50 (0.84%)
Bid:
1,137.00
Ask:
1,137.50
Spread: 0.50 (0.044%)
Market Cap: £9.61b
SN. Live PriceLast checked at - London Stock Exchange

Intraday Smith & Nephew Share Chart

Transaction in Own Shares

15 May 2026 11:41

RNS Number : 5483E
Smith & Nephew Plc
15 May 2026
Β 

15 May 2026

Smith & Nephew plcTransactions in own shares

Β 

Smith & Nephew plc (the "Company") announces that from 8 May 2026 up to and including 14 May 2026 it has purchased the following number of its own ordinary shares of US 20Β’ each through Merrill Lynch International, as part of its USD $250 million share buyback programme announced on 6 May 2026 and in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 6 May 2026.

Β 

Date of purchase

Aggregate number of ordinary shares purchased

Lowest price paid per ordinary share

Highest price paid per ordinary share

Average price paid per ordinary share

8 May 2026

285,558

1,085.50p

1,116.50p

1,099.92p

11 May 2026

297,890

1,070.50p

1,098.50p

1,081.92p

12 May 2026

275,463

1,062.50p

1,104.00p

1,088.00p

13 May 2026

283,073

1,097.50p

1,112.50p

1,102.19p

14 May 2026

283,817

1,097.00p

1,108.50p

1,103.16p

Β 

The Company intends to hold these shares in Treasury and then either cancel them or retain them for the purpose of satisfying awards under the Company's employee share plans.

Β 

Since 8 May 2026, the Company has purchased 1,425,801 shares at a cost of $21,165,361.30.

Β 

Following the purchases of these shares, the Company holds 25,110,406 of its ordinary shares in treasury. The Company's issued share capital, with one voting right per share consists of 852,623,344 ordinary shares of US20Β’ each (excluding treasury shares). The figure of 852,623,344 should be used by shareholders as the denominator when determining whether they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Β 

These purchases were made by Merrill Lynch International on behalf of the Company.

This announcement is made in accordance with the requirements of UKLR 9.6.6R.

The table below contains detailed information about the purchases made as part of the buyback programme.

Β 

Schedule of Purchases

Β 

Shares purchased: 1,425,801 (ISIN: GB0009223206)

Β 

Dates of purchases: 8 May 2026 to 14 May 2026

Β 

Investment firm: Merrill Lynch International

Β 

Aggregate information:

Β 

Venue

Volume weighted average price paid per ordinary share (GBP)

Number of ordinary shares repurchased

Lowest price per ordinary share (GBP)

Highest price per ordinary share (GBP)

London Stock Exchange

10.9495

1,425,801

10.6250

11.1650

CBOE Europe BXE

-

-

-

-

CBOE Europe CXE

-

-

-

-

Turquoise

-

-

-

-

Aquis Stock Exchange

-

-

-

-

Β 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), a schedule of individual trades by Merrill Lynch International is available below:

Β 

Individual Transactions:

The table attached contains detailed information of the individual trades made by Merrill Lynch International, as part of the buyback programme.

Click on, or paste the following link into your web browser, to view the associated PDF document.

[RNS to insert link]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
POSSFAFSIEMSEDI
Date   Source Headline
10th Jul 202612:01 pmRNSTransaction in Own Shares
3rd Jul 20269:07 amRNSTransaction in Own Shares
2nd Jul 20269:16 amRNSBlock Admission Application
1st Jul 202611:09 amRNSTotal Voting Rights
30th Jun 202610:07 amRNSHolding(s) in Company
26th Jun 20269:54 amRNSTransaction in Own Shares
26th Jun 20269:52 amRNSHolding(s) in Company
19th Jun 20269:21 amRNSTransaction in Own Shares
17th Jun 20269:03 amRNSHolding(s) in Company
12th Jun 202610:18 amRNSTransaction in Own Shares
11th Jun 20268:42 amRNSHolding(s) in Company
5th Jun 202612:12 pmRNSTransaction in Own Shares
4th Jun 20264:05 pmRNSDirector/PDMR Shareholding
3rd Jun 202611:21 amRNSDirector/PDMR Shareholding
3rd Jun 202610:35 amRNSAdmission to Trading
1st Jun 20263:10 pmRNSTotal Voting Rights
29th May 202610:37 amRNSTransaction in Own Shares
27th May 20269:31 amRNSPre Stabilisation Notice
22nd May 20261:32 pmRNSAdmission to Trading
22nd May 20269:58 amRNSTransaction in Own Shares
20th May 202611:25 amRNSDirector/PDMR Shareholding
19th May 20268:53 amRNSHolding(s) in Company
15th May 202612:28 pmRNSTransaction in Own Shares Replacement
15th May 202611:41 amRNSTransaction in Own Shares
14th May 20269:25 amRNSHolding(s) in Company
12th May 20264:03 pmRNSSterling Amount of Dividend
8th May 20267:00 amRNSShare Buyback Programme
6th May 20262:25 pmRNSResult of AGM
6th May 20267:00 amRNSSmith+Nephew First Quarter 2026 Trading Update
1st May 20261:10 pmRNSTotal Voting Rights
27th Apr 20267:00 amRNSExpert surgeons insights event for investors
22nd Apr 20268:46 amRNSNotice of Results
16th Apr 202611:12 amRNSDirector/PDMR Shareholding
15th Apr 20263:46 pmRNSDirector Declaration
14th Apr 20262:59 pmRNSReplacement: Annual Financial Report & AGM Notice
1st Apr 202612:23 pmRNSTotal Voting Rights
24th Mar 20264:16 pmRNSDirector/PDMR Shareholding
24th Mar 20268:45 amRNSHolding(s) in Company
16th Mar 20263:08 pmRNSAnnual Financial Report & Notice of AGM
16th Mar 20263:08 pmRNSAnnual Financial Report & Notice of AGM
10th Mar 20262:30 pmRNS-RSmith+Nephew launches next-generation ALLEVYN™ COMPLETE CARE Foam Dressing - designed for high performance in wound management and pressure injury prevention
5th Mar 20267:30 amRNSDirector Declaration
2nd Mar 20261:36 pmRNSTotal Voting Rights
2nd Mar 20267:00 amRNSFinal Results
5th Feb 202611:56 amRNSNotice of Results
2nd Feb 20264:00 pmRNSBLOCK LISTING SIX MONTHLY RETURN
2nd Feb 20263:05 pmRNSTotal Voting Rights
23rd Jan 20262:00 pmRNSDirector/PDMR Shareholding
21st Jan 20264:11 pmRNSCompletion of Acquisition
12th Jan 20264:30 pmRNSAcquisition of Integrity Orthopaedics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.